Tila

Din il-poeżija bl-isem ` Tila’ ta’ Jane Micallef dehret fil-ġurnal Il-Malti : Rivista tal-Akkademja tal-Malti ħarġa letterarja, 93.peer-reviewe

Żwiemel

Din il-poeżija bl-isem ` Żwiemel’ ta’ Jane Micallef dehret fil-ġurnal Il-Malti : Rivista tal-Akkademja tal-Malti ħarġa letterarja, 93.peer-reviewe

Karmenu (... jew isem ieħor)

Din il-poeżija bl-isem ` Karmenu (... jew isem ieħor)’ ta’ Jane Micallef dehret fil-ġurnal Il-Malti : Rivista tal-Akkademja tal-Malti ħarġa letterarja, 93.peer-reviewe

Totarol content and cytotoxicity varies significantly in different types of propolis

Propolis is a complex honeybee product deposited in the beehives, where it protects the hive and its occupants from microbial infection. Propolis has several reported medical applications in view of its numerous bioactive properties. The water insoluble fraction of crude Maltese honeybee propolis was extracted in methanol. Analysis by gas chromatography – mass spectrometry (GC-MS) showed the diterpenoid totarol to be the predominant constituent in all samples. The evaporated methanol residue was dissolved in dimethyl sulphoxide (DMSO) and used for cytotoxicity testing on human cancer cell lines using standard 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) assays. Results obtained show that the propolis collected from Malta has cytotoxic activity in cancer cells in vitro. However, propolis collected from different sites, only a few miles apart and at different times of the year, showed marked variations in the cytotoxicity, which correlated clearly with totarol content. This reflects the differences in the species of plants, on which the bees had foraged and indicates the importance of collection site and season of collection on the bioactivity of propolis products.peer-reviewe

Polymer-tethered glyconanoparticle colourimetric biosensors for lectin binding : structural and experimental parameters to ensure a robust output

Glycan–lectin interactions play essential roles in biology; as the site of attachment for pathogens, cell–cell communication, and as crucial players in the immune system. Identifying if a new glycan (natural or unnatural) binds a protein partner, or if a new protein (or mutant) binds a glycan remains a non-trivial problem, with few accessible or low-cost tools available. Micro-arrays allow for the interrogation of 100's of glycans but are not widely available in individual laboratories. Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive. Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers have emerged as biosensors to detect glycan–protein binding, based on colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye. Despite the large number of reports there are no standard protocols for each system or recommended start points, to allow a new user to deploy this technology. Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers. This work aimed to remove the need to explore chemical and nanoparticle space and hence remove a barrier for other users when deploying this system. We show that the concentration of the gold core is crucial to balance strong responses versus false positives and recommend a gold core size and polymer tether length which balances sufficient colloidal stability and output. Whilst subtle differences between glycans/lectins will impact the outcomes, these parameters should enable a lab user to quickly evaluate binding using minimal quantities of the glycan and lectin, to select candidates for further study

A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae

Interstitial lung disease and associated fibrosis occur in a proportion of individuals who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection through unknown mechanisms. We studied individuals with severe coronavirus disease 2019 (COVID-19) after recovery from acute illness. Individuals with evidence of interstitial lung changes at 3 to 6 months after recovery had an up-regulated neutrophil-associated immune signature including increased chemokines, proteases, and markers of neutrophil extracellular traps that were detectable in the blood. Similar pathways were enriched in the upper airway with a concomitant increase in antiviral type I interferon signaling. Interaction analysis of the peripheral phosphoproteome identified enriched kinases critical for neutrophil inflammatory pathways. Evaluation of these individuals at 12 months after recovery indicated that a subset of the individuals had not yet achieved full normalization of radiological and functional changes. These data provide insight into mechanisms driving development of pulmonary sequelae during and after COVID-19 and provide a rational basis for development of targeted approaches to prevent long-term complications

Sunetti ta’ William Shakespeare

Ġabra ta’ poeżiji u proża li tinkludi: Grand Prix ta’ Carmel Azzopardi – Pizza marinara ta’ Carmel Azzopardi – Ħajku ta’ Kit Azzopardi – Ix-xemgħa qiegħda ta’ Charles Bezzina – U taħti ramel, ramel ta’ Charles Bezzina – Vażett ta’ Ġorġ Borg – Bniedem li mhux ta’ Ġorġ Borg – Il-ħajbu ta’ Antoine Cassar – Il-mistoħbija ta’ Manwel Cassar – Għasel ta’ Carmel G. Cauchi – Dgħajsa ta’ Carmel G. Cauchi – Ħitan ta’ Alfred Degabriele – Skeletru silwett...f’realtà moħbija ta’ Stefano Farrugia – Minjatura tal-enimmi ta’ Stefano Farrugia – Mnejn jgħaddi Kristu ta’ Joe Friggieri – Rebbiegħa ta’ Reno Fenech – Blogger ta’ Charles Flores – Veġeterjana ta’ Charles Flores – Mejju ta’ Joe P. Galea – Kien hemm lejla u tmien nisa ta’ Claudia Gauci – Ħobbni ta’ Sergio Grech – Mitlufin ta’ Maria Grech Ganado – Moħħi ta’ Maria Grech Ganado – Viżjoni ta’ Maria Grech Ganado – Inkontinenza ta’ Adrian Grima – Andrew jħebb in-nar ta’ Adrian Grima – It-Tlieta, 20 ta’ Lulju 2004 ta’ Alfred Massa – Fuq l-għolja tal- Verdala ta’ Jane Micallef – Imm’issa ta’ Jane Micallef – Baby blues ta’ Immanuel Mifsud – Ġo dar sawra ta’ Immanuel Mifsud – Lil Dun Karm ta’ Maurice Mifsud Bonnici – Il-fuklar ta’ Achille Mizzi – Ut videam ta’ Achille Mizzi – Karnival solitarju ta’ Patrick Sammut – Mill-baħħ etern ta’ Joe Zammit Tabona – ...fil-ħmieġ ta’ ftit blatiet... ta’ Paul P. Borg – Bħall-qasab ta’ Steve Borg – L-aħħar żjara ta’ Victor Fenech – Ħelwa.morra 18 ta’ Ann Marie Schembri – Jack & Jill ta’ Trevor Żahra – Għadbilura ta’ Russell Davis, traduzzjoni ta’ Toni Aquilina – Sunetti ta’ William Shakespeare, traduzzjoni ta’ Oliver Friggieri.peer-reviewe

Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations

Purpose To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics. Patients and Methods One thousand thirty-three patients were randomly assigned to intensified (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) or standard (daunorubicin and Ara-C [DA]) induction chemotherapy, with one or two doses of gemtuzumab ozogamicin (GO). The primary end point was overall survival (OS). Results There was no difference in remission rate after two courses between FLAG-Ida + GO and DA + GO (complete remission [CR] + CR with incomplete hematologic recovery 93% v 91%) or in day 60 mortality (4.3% v 4.6%). There was no difference in OS (66% v 63%; P = .41); however, the risk of relapse was lower with FLAG-Ida + GO (24% v 41%; P < .001) and 3-year event-free survival was higher (57% v 45%; P < .001). In patients with an NPM1 mutation (30%), 3-year OS was significantly higher with FLAG-Ida + GO (82% v 64%; P = .005). NPM1 measurable residual disease (MRD) clearance was also greater, with 88% versus 77% becoming MRD-negative in peripheral blood after cycle 2 (P = .02). Three-year OS was also higher in patients with a FLT3 mutation (64% v 54%; P = .047). Fewer transplants were performed in patients receiving FLAG-Ida + GO (238 v 278; P = .02). There was no difference in outcome according to the number of GO doses, although NPM1 MRD clearance was higher with two doses in the DA arm. Patients with core binding factor AML treated with DA and one dose of GO had a 3-year OS of 96% with no survival benefit from FLAG-Ida + GO. Conclusion Overall, FLAG-Ida + GO significantly reduced relapse without improving OS. However, exploratory analyses show that patients with NPM1 and FLT3 mutations had substantial improvements in OS. By contrast, in patients with core binding factor AML, outcomes were excellent with DA + GO with no FLAG-Ida benefit

RNA backbone: Consensus all-angle conformers and modular string nomenclature (an RNA Ontology Consortium contribution)

A consensus classification and nomenclature are defined for RNA backbone structure using all of the backbone torsion angles. By a consensus of several independent analysis methods, 46 discrete conformers are identified as suitably clustered in a quality-filtered, multidimensional dihedral angle distribution. Most of these conformers represent identifiable features or roles within RNA structures. The conformers are given two-character names that reflect the seven-angle δεζαβγδ combinations empirically found favorable for the sugar-to-sugar “suite” unit within which the angle correlations are strongest (e.g., 1a for A-form, 5z for the start of S-motifs). Since the half-nucleotides are specified by a number for δεζ and a lowercase letter for αβγδ, this modular system can also be parsed to describe traditional nucleotide units (e.g., a1) or the dinucleotides (e.g., a1a1) that are especially useful at the level of crystallographic map fitting. This nomenclature can also be written as a string with two-character suite names between the uppercase letters of the base sequence (N1aG1gN1aR1aA1cN1a for a GNRA tetraloop), facilitating bioinformatic comparisons. Cluster means, standard deviations, coordinates, and examples are made available, as well as the Suitename software that assigns suite conformer names and conformer match quality (suiteness) from atomic coordinates. The RNA Ontology Consortium will combine this new backbone system with others that define base pairs, base-stacking, and hydrogen-bond relationships to provide a full description of RNA structural motifs